Takeda unveils new dengue vaccine manufacturing plant in GermanyChristian Fernsby ▼ | November 10, 2019
Takeda Pharmaceutical Company announced the opening of its new manufacturing plant in Singen, Germany, for its dengue vaccine candidate, TAK-003.
Pharmaceuticals Singen vaccine plant
Topics: Takeda dengue vaccine plant Germany
Takeda invested more than 130 million Euro and will employ up to 200 employees in the vaccine plant.
According to the World Health Organization (WHO), dengue is the fastest spreading mosquito-borne viral disease, which is estimated to cause approximately 390 million infections and 20,000 deaths globally each year.
Takeda’s dengue vaccine candidate is currently being investigated in the pivotal Phase 3, multi-centered, global, double blind, randomized, placebo-controlled trial to evaluate the efficacy, safety and immunogenicity of a tetravalent dengue vaccine administered subcutaneously in healthy children. ■